Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If you're referring to the OA Pain trials, they were expanded due to inefficacy of low doses (below 5mg). In order to satisfy endpoints, doses will be increased (10mg, +) to show CR845's efficacy. There will be very little news over the next several months due to timing of upcoming catalysts. I suspect the earnings report will be our next and final catalyst until january, and given the need to expand the OA trials, i suspect the earnings call will disappoint (potential need for funding sooner than the initial 2019 timeline given last call) and we should expect to see share price fall closer to the $10 range, possibly lower. If im wrong that would be nice- short term; however, if you're a believer in this team you might appreciate the opportunity to acquire cheap shares- personally, I am. Cara long.
Good luck to all.
There are more sellers than buyers and the stock price is falling.
If CR845 fails, it is difficult to imagine how the company ever generates the financial backing to develop CR701.. but technically yes, "prospects" was a missleading word- sorry for the confusion. GLTA
Afraid not. At present, CR845 is the only drug CARA is actively progressing through trials, while CR701 (the cannabis drug to which you're referring, I presume) remains pre-clinical. Could be a big hit. Point is we're years away from ever knowing that and CARA's success or failure hinges on CR845, a kappa opioid. Please inquire if you have any questions or need further explanation.
None of CARA's current prospects have any involvement with medical marijuana... have you ever heard of CR845? Or are you just here to pump?
Please elaborate ?
I'm in. Love everything about this company and the potential of their technology, specifically regarding the quickshot for testosterone deficiency.. I suspect folks will be 'surprised' by the earnings potential this market holds as Antares begins to report over the next couple years..
Never encouraging whwn your president sells over 25,000 shares...
Wow... and here i was considering re-claiming a stake in this company. I see the current situation is still a total laughing stock- no offense to current holders/longs. But my god, how inept can a company BE? Doing over a billion in revs and somehow still can't decipher their asses from their feet... SMH
Any positive news to report?? I am genuinely interested in an OPKO comeback, would like to be a part of it, but mostly I believe the stock- at its current share price levels- can't possibly be beaten any lower (maybe im wrong!!).
I wish you all the best.
Thanks
As a long i appreciate optimism, but with all due respect this sounds pump-ish. Let's try and be nice and honest on this board
Thanks Dj! I recognize you from the ZYNE and CARA boards for awhile now, im long on CARA, cashed in on zyne earlier this year... we'd sure love to have you back on chalmers team!!
...CARA's phase 2 OA trial had nothing to do with CBD's... fyi...
hey guys- can anyone explain the Amended Statement of Ownership document posted today?! Please advise!!
Agreed Marc. As surprised as i am in the magnitude of our drop, there doesn't seem to be any slowing down... i wouldnt try to catch this one, patiently waiting for us to find support (10-11? 9-10? 6-8?) and begin to re-buy. Today, i have finally fallen below my cost basis.
Our post op IV pain trials- which lacks the conplexity/difficulty of orally administered CR845, has proven to lower morphine/rescue med demand in patients and therefore warrants serious attention- will be complete in Q4 and we should hear something by year's end. Phase 3 Pruritus is still recruiting, and so I wouldnt expect to hear a readout or anything concrete until we're into 2018, 6+ months.. these large spaces of time without catalysts will see us look for a bottom for support, we'll have to wait and see where that is. However, i maintain my attitude that this should be viewed as an opportunity rather than a "panic."
As a long, I am absolutely astounded at the price on offer for Cara shares after a hilariously “rough” week. As someone who was always highly skeptical of CR845 treating pain, specifically the tablets- I was never impressed with their performances in previously posted trials- I guess its simply the case THAT many people who bought in during the run to $28 were simply THAT uninformed. There seems to be some misperceived notion that CARA is attempting to “fix” the opioid epidemic. While a lovely thought indeed, this was never the goal for management; they were always VERY upfront with us about their agenda, and there was an emphasis placed in pruritus that the general public doesn’t seem to “get.” While we're still years away (and whats the hurry!) from potential revenue, you HAVE to see the light at the end of the tunnel via pruritus. Please look at a potential, hypothetical situation with me: 660,000 (number of CKD patients in United States alone*) receiving dialysis (weekly). If 15% of these patients (a VERY modest figure relative to initial pain trial indications of efficacy) accept weekly treatment of CR845 (52 doses administered per patient per year) that is 99,000 patients treated x 52 doses for 5148000 annual doses administered. With an average cost of $72 per treatment (this $ figure is the current mean of costs for pain meds administered in hospitals), the yearly revenue for CR845 for pruritus alone would be $370MM. That’s with ONLY 15% of the current market accepting treatment. The FDA granting Breakthrough status for IV Pruritus should not be taken lightly, rather should serve as an indication that the 15% figure will be much higher in actuality (42% takes us over a billion, does anyone know what average market share most successful drugs granted FDA Breakthrough status typically capture? Presumably it’s larger than 15%). Thus, I am as overjoyed for the abundancy of cheap shares available to me as I am bewildered at the naivety of market players today and these tourist/short term investors lack of interest in understanding biotechs beyond the cheap, shallow headline-driven articles they’re reading via a Google search…
To all the longs- have a wonderful weekend,
Cara strong.
Not sure i see the validity in some of the article's claims, right off the bat the "funding running out in 2018." Management hasn't said anything to indicate they weren't covered though 2019 following the public offering this spring. Alot of folks want a piece of CARA-short because of our "failed phase 2 study," but i maintain my belief that our drop in SP was way overdone and our results in pruritus alone validate this company's prospects and future success...
anybody out there?
Appreciate this feedback!!! I feel the same way: minus the medical qualifications & specific citations you just provided us... Thanks for the post, doc
FDA requires low doses in testing, so 1mg and 2mg were mandatory, and their inefficacy versus placebo resulted in the stock bombing; this totally overshadowed the positives behind the 5mg dose's significance. While some are saying it was poor judgement on CARA's part to implement these low dose levels, these individuals are ill-informed of the industry. The results of this phase were FINE- no better no worse- and we will see a larger dose(s) applied in the next phase.
While the sell off was totally over done, i must admit, the buying leading up to these results was almost equally overdone. The share price should sit around $20 IMO, and i will continue to accumulate at this level, because i think CR845's efficacy in pruritus alone warrants investor's attention and respect. The market share CARA stands to acquire for itch alone is huge. I believe firmly that any wins CR845 endures against pain should be viewed as supplemental to this drug and this company's long-term potential.
I wont be going anywhere.
Good look to all.
Yeah, I understand. Remember all the insiders that bought common shares when we were under a buck, only a couple months ago.. I truly believe we've seen a bottom and any of these dips are buying opps. This is of course assuming that the RSV announcement in about August will be positive (and i feel strongly that it will be).
Why so quiet over on this board?
Why so quiet over on this board?
I know how frustrating these formalities seem when you're a shareholder watching from afar.. but remember that to every insider at NVAX, the current state of their share price isn't really a top priority NOW; what matters to the team is getting active pipeline drugs on track for success. And this will benefit everyone more in the long run. If you believe in the company and the team, you have to be patient, have faith, and wait.
I believe it was May, and the 90 days means we will wait as late as August to hear these results.
I see that now- my applogies.. thought you were one of those randos coming here to pump something. My mistake
Whatr you high?? Our stock here in CARA has run about 50% in a week- take it outside, dude
Going by some of Derek's comments in that video regarding efficacy of CR845, it seems the best of news could be yet to come, as we continue to await OA results
Are he expired options related at all to the options exercised by the insiders back in march? Choosing not to execute on them? Or am i totally off base- dont know anything about options..
..Slightly abnormal close today..
Citron can kiss my DICK
Well technically speaking, if most recent trial results don't live up to the [now] lofty expectations the share price can fall well below "15's." Of course if this happens, i wouldn't recommend buying at all, regardless of the discounted price..
Moreover, in today's times and the state of the government in virtually disarray, promises for economic reform potentially unfulfilled due perpetual investigations into our president (or impeachment?)... There is no way to know this stock or the sector or the market altogether can't come falling down...
I guess my point is this. Why are you hung up on the number $15? Either you believe in this company's pursuit or not. Sure "something could happen" and we revisit a lower teen (or even lower!), but i certainly wouldn't bet on it, with trial results pending that could single handily move the SP up 25% in a day.
If you like the company at $15, you should like them at $18 or $20
Was their any clarification given on last CC regarding the status of the HGH trial(s)?
...And the daily buying from Frost, which at first felt like a nice bode of confidence some many months ago, has now just pushed further my belief that the man is totally delusional and senile - and i mean that with all respect due to someone who has made some great accomplishments in his lifetime; it is not my intention to playfully insult Frost..
..Interested in hearing from anyone who feels with conviction that I'm wrong..
I understand a company in this industry doing a billion in revenue "seems" like potential. But the behavior of management is the most unprofessional I've seen anywhere, of any company, public or private (Example: making a whimsical comment about entering animal market, then never entering the market, seemingly, nor ever addressing this comment ever again).
So to your point, I agree - on paper, this company is doing a billion in revs while carrying no debt - $6 is cheap, by these measures alone...
But based on recent past performance (since BRLI acquisition) nothing has worked out. The great Doc refers to all these products (4KScore, Rayaldee) as these blockbuster game changing drugs, but clearly NOONE ELSE in the industry agrees!!!! And despite lackluster sales, noone on the conference calls has anything concrete/motivating to say regarding a turnaround.... just that "they're all so pleased with the progress.."
The conference calls of OPKO were probably the worst part of holding the stock- second to the amount of money I lost- as it was the closest i've come to a slap in the face over the phone...
So ultimately, yeah, i just fail to see where the upside lies - what is the catalyst that changes all this? A major board overhaul? Okay...
The only thing i can think of to motivate anyone considering this stock is 'it cant get any worse.'
But i said that at $9 and $8 and $7.....
So Christ- Maybe it can get worse?
Best of luck all longs.
You're sharing an article dated over 3 months ago... It's insulting to this board, and the longs who've been pounded into the ground holding this for the last 2 years.
Any progress in a BOD total overhaul?
Best of luck all,
Glad i got out of this when i did. I was reluctant to accept such a loss for my largest holding. Honestly, I dont see how there's any floor here. Mid 6's a bargain? I dont know, maybe-maybe not. But this company is A JOKE. I am not a short nor do i intend to offend any longs - like i said i once was one - but honestly how do you justify holding this stock anymore? Management is so bad it is offensive, complete disregard for shareholders.
THAT BEING SAID- is there potential here with a major overhaul of the current staff? That is quite possible, but idk. Curious to hear anyone's thoughts.
Good luck to all
Selling OPK was the best thing that happened to me... checking in to see how things went after the CC... my condolences to all longs. Dont convince yourself things will "turn around," i believe this company/management is truly delusional/inept..
Maybe it is the bottom, maybe not. But it should be of no great consequence .. what makes this an enticing play to shorts is that we've had just about all the good news we can, near-term..with trial updates not expected until our Q2 call (3 months approx), there's essentially 0 catalysts to drive the SP near-term; this coupled with a recent history of sub-par earnings calls (excessive cash burn, obviously no revenue to report), i "get" the short interest. Long and strong for me though.
Over the last month....25-30% SP drop off GREAT press and institutional buys = shakeout. Typical WS greed. Feeling great about our future. Long.